Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Guangdong Zhanjiang Jimin Pharmaceutical Co., Ltd.
WARNING LETTER
•Guangdong Zhanjiang Jimin Pharmaceutical Co., Ltd.•May 19, 2017

Guangdong Zhanjiang Jimin Pharmaceutical Co., Ltd. – FDA Warning Letter, May 19, 2017

Record Details

The FDA inspected Guangdong Zhanjiang Jimin Pharmaceutical Co., Ltd. from May 15-19, 2017, identifying significant CGMP violations for finished pharmaceuticals, rendering their drug products adulterated.

Key violations include: 1. **Inadequate Quality Control Unit (21 CFR 211.22(a)):** The firm's quality unit approved multiple lots of an OTC drug product labeled with hydrocortisone but containing dexamethasone acetate, due to a claimed "translation mistake." While a recall occurred, the firm failed to provide a detailed investigation or recurrence prevention plan. 2. **Failure to Test Drug Products (21 CFR 211.165(a)):** The firm did not test drug products for identity and strength of active ingredients prior to release. 3. **Inadequate Production and Process Control Procedures (21 CFR 211.100(a)):** The firm lacked validated manufacturing processes, process performance qualification studies, and an ongoing program for monitoring process control.

The firm's August 16, 2017, response was deemed inadequate, lacking details on quality control test methods, commitment to comprehensive testing, and timelines for process validation. The FDA strongly recommended engaging a qualified CGMP consultant.

Additionally, the firm manufactures and distributes "Piyanping Anti-Itch Lotion," which is an unapproved new drug and misbranded. It is labeled

Company
Guangdong Zhanjiang Jimin Pharmaceutical Co., Ltd.
Inspection date
May 19, 2017
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 1efb1498-fb9a-4bd7-9275-c5a70f7e0886

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.22(a)21 CFR 211.165(a)21 CFR 211.100(a)21 U.S.C. 35221 U.S.C. 35521 U.S.C. 321(g)(1)(B)21 U.S.C. 321(g)(1)(C)

Full citation text and observation details available on the Dashboard.

Other documents for Guangdong Zhanjiang Jimin Pharmaceutical Co., Ltd.
  • 483 - 2017-05-19May 19, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Guangdong Zhanjiang Jimin Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.